GlassScriptPhysician profile
Joseph J Blasiol
NPI 1124055231
$8,918.26
in general payments reported to CMS, 2019-2025
33 companies · $933 in 2025
The $933 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $1,078 · 2021: $1,513 · 2022: $1,362 · 2023: $1,634 · 2024: $1,077 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,599 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,599.01 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,994.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,173.26 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,019.44 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Lilly USA, LLC | $776.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $717.83 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $716.88 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $353.89 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $318.85 | 2019-2023 | Xarelto |
| Allergan, INC. | $254.19 | 2019-2020 | |
| Glaxosmithkline, LLC. | $222.52 | 2020-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $186.36 | 2019-2023 | |
| Amarin Pharma, INC. | $174.70 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $127.16 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $103.35 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $86.14 | 2024-2025 | Veozah |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $85.23 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $79.70 | 2020-2024 | Zoryve |
| Novartis Pharmaceuticals Corporation | $71.77 | 2020-2023 | |
| Sanofi Pasteur INC. | $61.54 | 2023-2024 | |
| Exact Sciences Corporation | $57.53 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $48.35 | 2024 | Voquezna |
| Bausch Health US, LLC | $35.43 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $31.24 | 2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2019 | |
| Pulmonx Corporation | $28.71 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $27.90 | 2022-2023 | Quviviq |
| Scpharmaceuticals INC. | $24.83 | 2025 | |
| Linus Health, INC. | $21.93 | 2023 | |
| Jazz Pharmaceuticals INC. | $21.01 | 2022 | |
| Abbott Laboratories | $14.44 | 2021 | |
| Amgen INC. | $13.93 | 2019 | |
| Biodelivery Sciences International, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Blasiol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.